ReviewJournal of medical virology2026
EBV Genome Variations and Association With Diseases.
Review in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The Epstein-Barr virus (EBV) is associated with a range of diseases, including malignancies and autoimmune disorders. Driven by advances in deep sequencing technologies, recent studies have systematically characterized EBV genomic landscapes in diverse clinical specimens, uncovering distinct geographic patterns in strain distribution. However, a comprehensive understanding of how EBV genomic variation contributes to disease pathogenesis remains incomplete. This review aims to consolidate current knowledge on EBV genomic variation and its role in disease development. First, we delineate the evolutionary origins of EBV genetic variations, focusing on key factors such as replication errors, recombination, and immune-driven selection. Next, we summarize the association between EBV subtypes and diseases, with evidence linking specific genetic variations to malignancies, infectious mononucleosis, and multiple sclerosis. At the mechanistic level, EBV genomic variation may influence pathogenesis through three interconnected mechanisms: viral functional changes, viral-host interactions, and molecular mimicry. Finally, this review explores how genomic insights into EBV can inform clinical applications, including early diagnostic biomarkers and next-generation therapies targeting lineage-specific variations, such as mRNA vaccines and small molecules that disrupt latency. These advances highlight the critical role of EBV genomics in understanding disease mechanisms and developing precision interventions to address the global burden of EBV-related diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.